Meet us at…
Latest news
Laurie Perdigon (1) , Manon Barthe (1) , Jean-Paul Thénot (1) , Franck Chiappini (2) , Agnes Choppin (2) , Hanan Osman-Ponchet (1) Occurrence of diffuse alveolar damage is a real storm in the course of pulmonary diseases leading to an acute and/or chronic inflammatory processes with poorly understood etiologies [...]
6 November 2024
Hanan Osman-Ponchet (1) , Laurie Perdigon (1) , Manon Barthe (1) , Ines Metatla (2) , Kevin Rogers (2) , Ida Chiara Guerrera (2) , Franck Chiappini (3) , Agnes Choppin (3) Pulmonary fibrosis is a progressive lung disease characterized by scarring and stiffening of lung tissue, ultimately leading to [...]
5 November 2024
OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).
25 March 2022
OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..
10 February 2022
OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.
8 October 2021
OTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.
29 June 2021
